Progress and Unfinished Business: Hepatitis B in the United States, 1980-2019

Bixler, Danae; Roberts, Henry; Panagiotakopoulos, Lakshmi; Nelson, Noele P.; Spradling, Philip R.; Teshale, Eyasu H.

doi:10.1177/00333549231175548

Cited by 4 publications

(1 citation statement)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A significant age difference was noted ( p < 0.001), with the co-infected group being younger (median age 33 vs. 35 years), which could affect the disease course and treatment response. Younger age in the co-infected group might also indicate recent transmission events in the context of lower immunity [ 27 ], particularly for Hepatitis B [ 28 ], necessitating further epidemiological investigation.…”

Section: Discussionmentioning

confidence: 99%

FibroScan® versus Biochemical Scores: A Study of Liver Fibrosis in HIV with HBV Co-Infection

Lungu,

Diaconescu,

Dumitrescu

et al. 2024

Microorganisms

View full text Add to dashboard Cite

The study aimed to determine liver fibrosis in human immunodeficiency virus (HIV) positive individuals using transient elastography (FibroScan®), Fibrosis-4 (FIB-4) score, and aspartate aminotransferase (AST) to Platelet Ratio Index (APRI) in the HIV Department from Infectious Diseases Hospital “Victor Babeș” Craiova, Romania. Of the analyzed HIV-positive subjects (n = 161), 93 (57.76%) had HIV mono-infection, and 68 (42.24%) had Hepatitis B Virus (HBV) co-infection. The prevalence of advanced liver fibrosis was higher (F2: 11.76% and F3: 13.24%, F4: 4.41%) in the HIV-HBV co-infected group compared to the HIV mono-infected group. The univariate and multivariate analysis identified HBV co-infection (OR = 5.73) male sex (OR = 5.34), serum aspartate amino-transferase levels (Pearson’s rho = 0.273), low platelet count (Pearson’s rho = −0.149) and erythrocyte sedimentation rate (OR = 1.030) as risk factors for the presence of liver fibrosis. Body mass index (OR = 1.08), serum lipid levels (OR = 0.96), viral load at diagnosis (OR = 1.00005), and low CD4+ cell count (OR = 0.977) were also correlated with liver fibrosis. The FIB-4 and APRI scores were strongly correlated with each other. In conclusion, HBV co-infection seems to be a determinant factor for liver fibrosis development in people living with HIV, together with other risk factors.

show abstract

Section: Discussionmentioning

confidence: 99%

FibroScan® versus Biochemical Scores: A Study of Liver Fibrosis in HIV with HBV Co-Infection

Lungu,

Diaconescu,

Dumitrescu

et al. 2024

Microorganisms

View full text Add to dashboard Cite

show abstract

Prevalence and awareness of Hepatitis B virus infection in the United States: January 2017 - March 2020

Bixler

Barker

Lewis

et al. 2023

Hepatology Communications

View full text Add to dashboard Cite

Background: Prevalence and awareness of HBV infection are important national indicators of progress toward hepatitis B elimination. Methods: National Health and Nutrition Examination Survey participants were examined for laboratory evidence of HBV infection (positive antibody to HBcAg and HBsAg), and interviewed to determine awareness of HBV infection. Estimates of HBV infection prevalence and awareness were calculated for the US population. Findings: Among National Health and Nutrition Examination Survey participants aged 6 years and older evaluated from January 2017 through March 2020, an estimated 0.2% had HBV infection; of these 50% were aware of their infection.

show abstract

Self‐reported hepatitis B testing among noninstitutionalized adults in the United States before the implementation of universal screening, 2013–2017: A nationwide population‐based study

Yendewa,

Salata,

Olasehinde

et al. 2024

Journal of Viral Hepatitis

View full text Add to dashboard Cite

In 2023, the US Centers for Disease Control and Prevention recommended universal screening for hepatitis B virus (HBV); however, the proportion of US adults screened before implementing this recommendation is unknown. We analysed nationally representative data from the National Health Interview Survey (2013–2017) on self‐reported HBV testing among noninstitutionalized US adults ≥18 years. We employed Poisson logistic regression to identify factors associated with self‐reported testing, using a conceptual framework that included four overarching factors: sociodemographic characteristics, healthcare access, health‐seeking behaviours and experiences, and access to internet‐based health information. Among 149,628 survey respondents, the self‐reported HBV testing rate was 27.2% (95% CI 26.2–28.7) and increased by 1.7% from 2013 to 2017 (p = .006). In adjusted analysis, health‐seeking behaviours and experiences had the strongest associations of self‐reported testing including a history of hepatitis (AOR 2.68, 95% CI 1.92–3.73), receipt of hepatitis B vaccination (AOR 5.11, 95% CI 4.61–5.68) and prior testing for hepatitis C (AOR 9.14, 95% CI 7.97–10.48) and HIV (AOR 2.69, 95% CI 2.44–2.97). Other factors associated with testing included being male (AOR 1.14, 95% CI 1.03–1.26), ages 30–44 years (AOR 1.37, 95% CI 1.17–1.61), 45–60 years (AOR 1.55, 95% CI 1.30–1.80) and ≥60 years (AOR 1.53, 95% CI 1.28–1.84), residence in the Western US region (AOR 1.23, 95% CI 1.06–1.43), and access to internet‐based health information (AOR 1.32, 95% CI 1.18–1.47). Being Hispanic was associated with lower odds of testing (AOR 0.80, 95% CI 0.66–0.97). These findings may help guide optimal HBV screening in the universal testing era.

show abstract

Progress and Unfinished Business: Hepatitis B in the United States, 1980-2019

Cited by 4 publications

References 62 publications

FibroScan® versus Biochemical Scores: A Study of Liver Fibrosis in HIV with HBV Co-Infection

FibroScan® versus Biochemical Scores: A Study of Liver Fibrosis in HIV with HBV Co-Infection

Prevalence and awareness of Hepatitis B virus infection in the United States: January 2017 - March 2020

Self‐reported hepatitis B testing among noninstitutionalized adults in the United States before the implementation of universal screening, 2013–2017: A nationwide population‐based study

Contact Info

Product

Resources

About